Terry Meriden
Endocrinology, Diabetes & Metabolism · Peoria, ILNPI 1467538231
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,283 of the $79,281 with a category attached, or 72.3%. 26 manufacturers reported payments, led by Novo Nordisk at 41.3% of the total. Reporting peaked in 2019 at $59,210 and has fallen 99.6% since, to $244 in 2025. Among endocrinology, diabetes & metabolism clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 269 payments — averaging $294.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$33K
- AbbVie$14K
- Amarin Pharma, Inc.$9K
- Dexcom, Inc.$9K
- Johnson & Johnson$8K
- Medtronic$1K
- plus $5K from 20 others
What the payments were for
- Consulting fees$4,8456%
- Speaking & faculty fees$57,28372%
- Travel & lodging$9,34612%
- Food & beverage$7,71710%
- Education$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 71 | $32,777 |
| AbbVie | 23 | $14,453 |
| Amarin Pharma, Inc. | 22 | $9,334 |
| Dexcom, Inc. | 15 | $8,928 |
| Johnson & Johnson | 17 | $7,783 |
| Medtronic(2 entities) | 12 | $1,359 |
| AstraZeneca | 16 | $1,086 |
| Sanofi-aventis U.S. LLC | 21 | $625 |
| Amgen | 11 | $476 |
| Corcept Therapeutics | 6 | $439 |
| Abbott | 16 | $341 |
| Regeneron | 3 | $244 |
| Ascensia Diabetes Care US Inc. | 2 | $219 |
| Lilly USA, LLC | 11 | $192 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $161 |
| Boehringer Ingelheim | 4 | $153 |
| Aytu Biopharma, Inc. | 2 | $135 |
| Bayer | 1 | $105 |
| Chiesi USA, Inc. | 1 | $94 |
| BD | 1 | $92 |
| Insulet Corporation | 5 | $81 |
| Ultragenyx Pharmaceutical Inc. | 1 | $77 |
| Shire North American Group Inc | 3 | $48 |
| Janssen Scientific Affairs, LLC | 1 | $46 |
| Valeritas, Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tresiba$21,661
- Vascepa$8,980
- INVOKANA$7,535
- DEXCOM CGM$5,132
- Ozempic$4,601
- Xultophy 100/3.6$3,635
- DEXCOM G6 CGM SYSTEM$3,634
- Synthroid$1,500
- Minimed 670G System$899
- FARXIGA$610
- RYBELSUS$391
- Korlym$340
- PRALUENT$214
- FREESTYLE LIBRE 3$135
- TZIELD$131
- Repatha$125
- Wegovy$120
- Natesto$115
- EVERSENSE E3 SENSOR KIT - RETAIL$110
- Kerendia$105
How this compares
$79,281 in reported general payments places this provider in the 90th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Other endocrinology, diabetes & metabolism in Peoria
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Babak PazookiJoliet$582K
- Ammar BayrakdarEvergreen Park$517K
- George BakrisChicago$403K
- Terrence SwadeLombard$369K
- Wenyu HuangChicago$341K
- Liana BillingsSkokie$295K
- Daniel SoArlington Heights$283K
- Silvana PannainChicago$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.